Therapeutic Reduction Mammoplasty: Experience of a Single Institute

Cureus. 2023 Jan 10;15(1):e33603. doi: 10.7759/cureus.33603. eCollection 2023 Jan.

Abstract

Introduction: Breast cancer is the most common malignancy in women worldwide as reported by the World Health Organization. The concept of oncoplastic breast surgery appeared as an extension of breast-conserving surgery, applying breast reduction techniques with more acceptable aesthetic and functional outcomes. The purpose of the present study was to describe the breast cancer population of a single institute submitted to lumpectomy and bilateral immediate breast reduction or mastopexy and its complications.

Material and methods: This is a retrospective observational study including patients submitted to lumpectomy and immediate bilateral breast reduction or mastopexy. Patients and tumour characteristics, surgical technique, complications, follow-up period, and recurrence data were obtained and analyzed.

Results: A total of 49 patients were submitted to lumpectomy and bilateral breast therapeutic reduction/mastopexy, with a mean age of 56.47 ±8.58 years and a mean body mass index of 28.68kg/m2 ±3.94 kg/m² between January 2019 and December 2021. Invasive tumours of no specific type, associated or not, with carcinoma intraductal in situ were the most common histological type corresponding to almost 80% of the cases with T1 stage corresponding to more than half of the cases. Sixteen percent of the patients had early minor complications with wound dehiscence associated with wound delayed healing, corresponding to 75% of the cases. Body mass index had a statistical difference between groups (p=0,006, t-test).

Conclusions: The low rates of minor and major complications show that immediate therapeutic breast reduction can be a suitable approach in selected cases.

Keywords: breast cancer management; oncoplastic breast surgery; reconstructive breast surgery; symmetrization mammaplasty; therapeutic mammoplasty.